AU2006262490A1 - Targets for inhibiting HCV replication - Google Patents

Targets for inhibiting HCV replication Download PDF

Info

Publication number
AU2006262490A1
AU2006262490A1 AU2006262490A AU2006262490A AU2006262490A1 AU 2006262490 A1 AU2006262490 A1 AU 2006262490A1 AU 2006262490 A AU2006262490 A AU 2006262490A AU 2006262490 A AU2006262490 A AU 2006262490A AU 2006262490 A1 AU2006262490 A1 AU 2006262490A1
Authority
AU
Australia
Prior art keywords
seq
hcv
protein
target protein
replication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006262490A
Inventor
Raffaele De Francesco
Amy S. Espeseth
Adam T. Gates
Daria Hazuda
Peter Linsley
Giovanni Migliaccio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Rosetta Inpharmatics LLC
Merck Sharp and Dohme LLC
Original Assignee
St Di Ricerche Di Biologia Molecolare P Angeletti SpA
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Rosetta Inpharmatics LLC
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Di Ricerche Di Biologia Molecolare P Angeletti SpA, Istituto di Ricerche di Biologia Molecolare P Angeletti SpA, Rosetta Inpharmatics LLC, Merck Sharp and Dohme LLC filed Critical St Di Ricerche Di Biologia Molecolare P Angeletti SpA
Publication of AU2006262490A1 publication Critical patent/AU2006262490A1/en
Assigned to MERCK SHARP & DOHME CORP., ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A., ROSETTA INPHARMATICS LLC reassignment MERCK SHARP & DOHME CORP. Alteration of Name(s) of Applicant(s) under S113 Assignors: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A., MERCK & CO., INC., ROSETTA INPHARMATICS LLC
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C12N2330/31—Libraries, arrays

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Description

WO 2007/001928 PCT/US2006/023646 TITLE OF THE INVENTION TARGETS FOR INHIBITING HCV REPLICATION RELATED APPLICATIONS The present application claims priority to U.S. Provisional Application No. 60/692,821, filed June 22, 2005, and U.S. Provisional Application No. 60/710,006, August 19, 2005, each of which are hereby incorporated by reference herein. BACKGROUND OF THE INVENTION The references cited in the present application are not admitted to be prior art to the claimed invention. Exposure to HCV results in an overt acute disease in a small percentage of cases, while in most instances the virus establishes a chronic infection causing liver inflammation and slowly progresses into liver failure and cirrhosis. (Iwarson, FEMS Microbiol. Rev., 14:201-204, 1994.) Epidemiological surveys indicate HCV plays an important role in hepatocellular carcinoma pathogenesis. (Kew, FEMS Microbiol. Rev., 14:211-220, 1994, Alter, Blood, 85:1681-1695, 1995.) The HCV genome consists of a single strand RNA about 9.5 kb in length, encoding a precursor polyprotein about 3000 amino acids. (Choo et al., Science, 244:362-364, 1989, Choo et al., Science, 244:359-362, 1989, Takamizawa et al. J. Virol., 65:1105-1113, 1991.) The HCV polyprotein contains the viral proteins in the order: C-E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B. Individual viral proteins are produced by proteolysis of the HCV polyprotein. Host cell proteases release the putative structural proteins C, El, E2, and p7, and create the N-terminus of NS2 at amino acid 810. (Mizushima et al., J. Virol., 68:2731-2734, 1994, Hijikata et al., Proc. Natl. Acad. Sci. USA., 90:10773-10777, 1993.) The non-structural proteins NS3, NS4A, NS4B, NS5A and NS5B presumably form the virus replication machinery and are released from the polyprotein. A zinc-dependent protease associated with NS2 and the N-terminus of NS3 is responsible for cleavage between NS2 and NS3. (Grakoui et al., J. Virol., 67:1385-1395, 1993, Hijikata et al., Proc. Natl. Acad. Sci. USA, 90:10773-10777, 1993.) A distinct serine protease located in the N-terminal domain of NS3 is responsible for proteolytic cleavages at the NS3/NS4A, NS4A/NS4B, NS4B/NS5A and NS5A/NS5B junctions. (Barthenschlager et al., J. Virol., 67:3835-3844, 1993, Grakoui et al., Proc. Natl. Acad. Sci. USA, 90:10583-10587, 1993, Tomei et al., J. Virol. 67:4017-4026, 1993.) RNA stimulated NTPase and helicase activities are located in the C-terminal domain of NS3. NS4A provides a cofactor for NS3 protease activity. (Failla et al., J. Virol., 68:3753 3760, 1994, De Francesco et al., U.S. Patent No. 5,739,002.) NS5A is a highly phosphorylated protein conferring interferon resistance. (Pawlotsky. J. Viral Hepat. Suppl., 1:47-48, 1999.) NS5B provides an RNA-dependent RNA polymerase. (De Francesco et al., International -1- WO 2007/001928 PCT/US2006/023646 Publication Number WO 96/37619, published November 28, 1996, Behrens et al., EMBO 15:12-22, 1996, Lohmann et al., Virology 249:108-118, 1998.) SUMMARY OF THE INVENTION Liver expressed proteins involved in HCV replication were identified using a procedure measuring the effect of inhibiting expression of host cell proteins on HCV replicon activity. The identified proteins and encoding nucleic acid provide targets for inhibiting HCV replication and for evaluating the ability of compounds to inhibit HCV replication. Compounds inhibiting HCV replication include compounds targeting identified proteins and compounds targeting nucleic acid encoding the identified protein. Several of the host genes identified as targets for inhibiting HCV replication were also found to be a target for inhibiting HIV replication. The ability to serve as a target for inhibiting both HIV and HCV replication indicates that such an identified gene and encoded protein may be a useful target for inhibiting replication of different types of viruses and not limited to inhibiting replication of a particular virus. Thus, a first aspect of the present invention describes a method of identifying a host cell factor involved in viral (e.g., HCV) replication using a short inhibitory RNA (siRNA) library. The method comprises the step of measuring the ability of a siRNA library targeting different cell factors to inhibit viral (e.g.,HCV) replication, wherein the siRNA library comprises at least 10 different siRNA's targeting a different host factor that was not previously associated with viral (e.g.,HCV) replication. A "library" contains a collection of different siRNA that is screened as part of an experiment. The experimental results are obtained at about the same time or over a limited time period. In different embodiments, the limited time period is within about a week or within about a day. Preferably, the members of the library are tested at the same time. Reference to the library comprising a certain number of siRNA targeting different host cell factors indicates that at least the indicated number of different siRNA are used. In different embodiments the library comprises 100, 500 or 1000 members and/or each of the different members is a kinase or phosphatase. In another embodiment, the library comprises 5000, 10000, or 20000 members and is considered to be a genome scale library. Another aspect of the present invention describes a method of evaluating the ability of a compound to inhibit replication of a virus. The method involves: (a) identifying a compound binding to, or inhibiting the activity or expression of, a target protein selected from the group consisting of: AKAP8 (SEQ ID NO: 11), ALK (SEQ ID NO: 67), ATM (SEQ ID NO: 68), C140RF24 (SEQ ID NO: 69), DGKD (SEQ ID NO: 15), DGKZ (SEQ ID NO: 70), DUSP19 (SEQ ID NO: 49), DUSP22 (SEQ ID NO: 71), DUSP6 (SEQ ID NO: 9), DUT (SEQ ID NO: 51), DYRK2 (SEQ ID NO: 72), DYRK4 (SEQ ID NO: 53), ENPP5 (SEQ ID NO: 73), EPHA2 (SEQ ID NO: 13), FGFR2 (SEQ ID NO: 74), FHIT (SEQ ID NO: 75), FRK (SEQ ID NO: 76), GAK (SEQ ID NO: 55), GCK (SEQ ID NO: 19), MAP2K3 (SEQ ID NO: 77), NME4 (SEQ ID NO: 1), PANK1 (SEQ ID NO: 78), PCK1 (SEQ ID NO: 3), PFKL (SEQ ID NO: 63), PIK4CA (SEQ ID NO: 21), -2- WO 2007/001928 PCT/US2006/023646 PRKWNK3 (SEQ ID NO: 5), PRPS1L1 (SEQ ID NO: 79), PSKH1 (SEQ ID NO: 57), PTK9L (SEQ ID NO: 80), SOCS5 (SEQ ID NO: 59), SRPK1 (SEQ ID NO: 17), STK16 (SEQ ID NO: 7), STK35 (SEQ ID NO: 81), TAF1 (SEQ ID NO: 82), TBK1 (SEQ ID NO: 83), TJP2 (SEQ ID NO: 84), TNK1 (SEQ ID NO: 61), TPK1 (SEQ ID NO: 85), TRIB3 (SEQ ID NO: 86), TRPM7 (SEQ ID NO: 87), VRK (SEQ ID NO: 88), ALPPL2 (SEQ ID NO: 89), AP4M1 (SEQ ID NO: 23), CAPZA1 (SEQ ID NO: 25), DNAH5 (SEQ ID NO: 27), DOM3Z (SEQ ID NO: 90), FTCD (SEQ ID NO: 29), PDIA3 (SEQ ID NO: 31), MDM4 (SEQ ID NO: 91), WDR66 (SEQ ID NO: 92), NOPS/NOP58 (SEQ ID NO: 33), NSUN6 (SEQ ID NO: 93), PAFAH1B1 (SEQ ID NO: 35), PARVB (SEQ ID NO: 37), PHEX (SEQ ID NO: 39), PKN1 (SEQ ID NO: 44), POLR2J2 (SEQ ID NOs: 41 or 65), RAB20 (SEQ ID NO 43), SYNPR (SEQ ID NO: 45), and TRPM5 (SEQ ID NO: 47); or a protein substantially similar to the target protein, wherein the substantially similar protein has a sequence identity of at least 95% to the target protein; and (b) determining the ability of the compound identified in step (a) to inhibit viral replication. The initial identification of a compound binding to, or inhibiting the activity or expression of a target protein, can be performed experimentally or based on known information concerning the ability of a compound to bind or inhibit one of the identified targets. Information on the different targets is available in the scientific literature. Preferably, the compound is initially identified as inhibiting activity. In preferred embodiments the virus is either HIV or HCV. Determining the ability of a compound to inhibit viral replication includes either, or both, (1) the initial identification of a compound as able to bind or inhibit viral replication or (2). determining the extent to which the compound inhibits viral replication. Inhibition of viral replication can be determined with quantitative or qualitative measurements. For example, determining the ability of a compound to inhibit HCV replication includes either, or both, (1) the initial identification of a compound as able to bind or inhibit HCV replication or (2) determining the extent to which the compound inhibits HCV replication. Sequence identity to a reference protein sequence is determined by aligning the protein sequence with the reference sequence and determining the number of identical amino acids in the corresponding regions. This number is divided by the total number of amino acids in the reference sequence (e.g., SEQ ID NO: 1) and then multiplied by 100 and rounded to the nearest whole number. Another aspect of the present invention describes a method of inhibiting HCV replication. The method employs an effective amount of a compound inhibiting the activity or expression of a target protein selected from the group consisting of: AKAP8 (SEQ ID NO: 11), ALK (SEQ ID NO: 67), ATM (SEQ ID NO: 68), C140RF24 (SEQ ID NO: 69), DGKD (SEQ ID NO: 15), DGKZ (SEQ ID NO: 70), DUSP19 (SEQ ID NO: 49), DUSP22 (SEQ ID NO: 71), DUSP6 (SEQ ID NO: 9), DUT (SEQ ID NO: 51), DYRK2 (SEQ ID NO: 72), DYRK4 (SEQ ID NO: 53), ENPP5 (SEQ ID NO: 73), EPHA2 (SEQ ID NO: 13), FGFR2 (SEQ ID NO: 74), FHIT (SEQ ID NO: 75, FRK (SEQ ID NO: 76), GAK (SEQ ID NO: 55), GCK (SEQ ID NO: 19), MAP2K3 (SEQ ID NO: 77), NME4 (SEQ ID NO: 1), PANK1 (SEQ ID NO: 78), PCK1 (SEQ ID NO: 3), PFKL (SEQ ID NO: 63), PIK4CA (SEQ ID NO: 21), -3- WO 2007/001928 PCT/US2006/023646 PRKWNK3 (SEQ ID NO: 5), PRPS1L1 (SEQ ID NO: 79), PSKH1 (SEQ ID NO: 57), PTK9L (SEQ ID NO: 80), SOCS5 (SEQ ID NO: 59), SRPK1 (SEQ ID NO: 17), STK16 (SEQ ID NO: 7), STK35 (SEQ ID NO: 81), TAF1 (SEQ ID NO: 82), TBK1 (SEQ ID NO: 83), TJP2 (SEQ ID NO: 84), TNK1 (SEQ ID NO: 61), TPK1 (SEQ ID NO: 85), TRIB3 (SEQ ID NO: 86), TRPM7 (SEQ ID NO: 87), VRK (SEQ ID NO: 88), ALPPL2 (SEQ ID NO: 89), AP4M1 (SEQ ID NO: 23), CAPZA1 (SEQ ID NO: 25), DNAH5 (SEQ ID NO: 27), DOM3Z (SEQ ID NO: 90), FTCD (SEQ ID NO: 29), PDIA3 (SEQ ID NO: 31), MDM4 (SEQ ID NO: 91), WDR66 (SEQ ID NO: 92), NOP5/NOP58 (SEQ ID NO: 33), NSUN6 (SEQ ID NO: 93), PAFAHIB 1 (SEQ ID NO: 35), PARVB (SEQ ID NO: 37), PHEX (SEQ ID NO: 39), PKN1 (SEQ ID NO: 44), POLR2J2 (SEQ ID NOs: 41 or 65), RAB20 (SEQ ID NO 43), SYNPR (SEQ ID NO: 45), and TRPM5 (SEQ ID NO: 47); or a protein substantially similar to the target protein, wherein the substantially similar protein has a sequence identity of at least 95% to the target protein. Another aspect of the present invention describes a method of inhibiting replication of a virus in a host. The host is provided with an effective amount of a compound able to inhibit the activity or expression of a target protein selected from the group consisting of: AKAP8 (SEQ ID NO: 11), ALK (SEQ ID NO: 67), ATM(SEQ ID NO: 68), C140RF24 (SEQ ID NO: 69), DGKD (SEQ ID NO: 15), DGKZ (SEQ ID NO: 70), DUSP19 (SEQ ID NO: 49), DUSP22 (SEQ ID NO: 71), DUSP6 (SEQ ID NO: 9), DUT (SEQ ID NO: 51), DYRK2 (SEQ ID NO: 72), DYRK4 (SEQ ID NO: 53), ENPP5 (SEQ ID NO: 73), EPHA2 (SEQ ID NO: 13), FGFR2 (SEQ ID NO: 74), FHIT (SEQ ID NO: 75), FRK (SEQ ID NO: 76), GAK (SEQ ID NO: 55), GCK (SEQ ID NO: 19), MAP2K3 (SEQ ID NO: 77), NME4 (SEQ ID NO: 1), PANK1 (SEQ ID NO: 78), PCK1 (SEQ ID NO: 3), PFKL (SEQ ID NO: 63), PIK4CA (SEQ ID NO: 21), PRKWNK3 (SEQ ID NO: 5), PRPS 1L1 (SEQ ID NO: 79), PSKH1 (SEQ ID NO: 57), PTK9L (SEQ ID NO: 80), SOCS5 (SEQ ID NO: 59), SRPK1 (SEQ ID NO: 17), STK16 (SEQ ID NO: 7), STK35 (SEQ ID NO: 81), TAF1 (SEQ ID NO: 82), TBK1 (SEQ ID NO: 83), TJP2 (SEQ ID NO: 84), TNK1 (SEQ ID NO: 61), TPKI(SEQ ID NO: 85), TRIB3 (SEQ ID NO: 86), TRPM7 (SEQ ID NO: 87), VRK (SEQ ID NO: 88), ALPPL2 (SEQ ID NO: 89), AP4M1 (SEQ ID NO: 23), CAPZA1 (SEQ ID NO: 25), DNAH5 (SEQ ID NO: 27), DOM3Z (SEQ ID NO: 90), FTCD (SEQ ID NO: 29), PDIA3 (SEQ ID NO: 31), MDM4 (SEQ ID NO: 91), WDR66 (SEQ ID NO: 92), NOP5/NOP58 (SEQ ID NO: 33), NSUN6 (SEQ ID NO: 93), PAFAH1B 1 (SEQ ID NO: 35), PARVB (SEQ ID NO: 37), PHEX (SEQ ID NO: 39), PKN1 (SEQ ID NO: 44), POLR2J2 (SEQ ID NOs: 41 or 65), RAB20 (SEQ ID NO 43), SYNPR (SEQ ID NO: 45), and TRPM5 (SEQ ID NO: 47); or a protein substantially similar to said target protein, wherein said substantially similar protein has a sequence identity of at least 95% to said target protein. Reference to "host" indicates a cell, animal, or human that is, or can be, infected with the virus. The compound can be administered prior to viral infection or to a host infected with the virus. Reference to open-ended terms such as "comprises" allows for additional elements or steps. Occasionally phrases such as "one or more" are used with or without open-ended terms to highlight the possibility of additional elements or steps. -4- WO 2007/001928 PCT/US2006/023646 Unless explicitly stated reference to terms such as "a" or "an" is not limited to one. For example, "a cell" does not exclude "cells". Occasionally phrases such as one or more are used to highlight the possible presence of a plurality. Other features and advantages of the present invention are apparent from the additional descriptions provided herein including the different examples. The provided examples illustrate different components and methodology useful in practicing the present invention. The examples do not limit the claimed invention. Based on the present disclosure the skilled artisan can identify and employ other components and methodology useful for practicing the present invention. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 provides results illustrating the time course for knockdown of PIK4CA mRNA levels and HCV RNA levels after transfection of siRNA targeting PIK4CA. Figure 2A provides results illustrating the production of a rabbit polyclonal antisera that recognizes PIK4CA protein. Figure 2B provides results showing inhibition of HCV replication after transfection of two separate siRNAs targeting PIK4CA, or an siRNA directly targeting HCV but not after transfection of a non-silencing siRNA (NS1). Figure 2C provides results showing that the siRNAs targeting PIK4CA used in figure 2B also knock down PIK4CA protein levels, but the siRNA targeting HCV and the nonsilencing siRNA (NS1) do not affect PIK4CA protein levels. Figure 3 provides resulting illustrating the ability of siRNA targeting different host genes to inhibit HIV replication. siRNA results for the following genes are provided in Figure 1: 1- CycT1; 2 PFKL; 3- PIK4CA; 4- DYRK4; 5- SYNPR; 6- GAK; 7- DUSPl9; 8- DUT; 9- PSKH1; 10- LUC; 11 SOCS5; 12- PARVB; and 13- TRPM5. DETAILED DESCRIPTION OF THE INVENTION Different host cell protein targets for inhibiting HCV replication were identified using a procedure measuring the effect of inhibiting expression of host cell protein on HCV replicon activity and taking into account liver expression of targeted proteins. The proteins identified as involved in HCV replication and the encoding nucleic acid provide targets for inhibiting HCV replication and for evaluating the ability of compounds to inhibit HCV replication. Several of the host genes identified as targets for inhibiting HCV replication were also found to inhibit HIV replication. The ability to serve as a target for both HIV and HCV indicates that such a target may be a useful target for inhibiting replication different types of viruses and not limited to a inhibiting replication of particular virus. Inhibiting viral replication, such as HIV and HCV, has research and therapeutic implications. Research applications include providing tools to study viral replication and expression, for example, HCV or HIV replication and expression. Therapeutic applications include using those compounds having appropriate pharmacological properties such as efficacy and lack of unacceptable toxicity to treat or inhibit onset of viral infection in a patient (e.g., HCV or HIV infection). -5- WO 2007/001928 PCT/US2006/023646 Identified Targets The targets for inhibiting viral replication, such as HCV replication, identified herein are host cell factors. Nucleic acid sequences encoding the identified host cell factors, host cell factors, and substantially similar nucleic acid or protein can be used as a target for inhibiting viral replication, such as HCV replication. Table 1 provides information on the identified host cell factors for inhibiting HCV replication, and in some cases HIIV replication. The targets provide in Table 1 may also be useful for inhibiting viral replication beyond HCV. A subset of the HCV targets were tested for inhibiting HIV replication. As described in Example 13, infra inhibition of PIK4CA, SYNPR, DYRK4, PFKL, GAK, DUSP19, and DUT also inhibited HIV replication. The ability to inhibit both HCV and HIV replication indicates a role for such target in the replication of different types of viruses. TABLE 1 Gene Acc. No. Amino acid Sequence Additional Information AKAP8 NM_005858 SEQ ID NO: 11 SEQ ID NO: 12, ORF= 62-2140 ALK NM_004304 SEQ ID NO: 67 ATM NM_000051 SEQ ID NO: 68 C140RF24 NM_173607 SEQ ID NO: 69 CSNK2A1 NM_001895 CSNK2B NM_001320 DDR1 NM_001954 DGKD NM_003648 SEQ ID NO: 15 SEQ ID NO: 16, ORF = 80-3592 DGKZ NM_003646 SEQ ID NO: 70 DUSP19 NM 080876 SEQ ID NO: 49 SEQ ID NO: 50, ORF=183-836 DUSP22 NM_020185 SEQ ID NO: 71 DUSP6 NM_001946 SEQ ID NO: 9 SEQ ID NO: 10, ORF = 481-1626 DUT NM_001948 DUT NM001948 SEQ ID NO: 51 SEQ ID NO: 52, ORF=85-579 DYRK2 NM 006482 SEQ ID NO: 72 DYRK4 NM_003845 SEQ ID NO: 53 SEQ ID NO: 54, ORF=161-1723 ENPP5 NM_021572 SEQ ID NO: 73 EPHA2 NM_004431 SEQ ID NO: 13 SEQ ID NO: 14, ORF = 138-3068 FGFR2 NM_000141 SEQ ID NO: 74 FHIT NM 002012 SEQ ID NO: 75 FRK NM_002031 SEQ ID NO: 76 GAK NM 005255 SEQ ID NO: 55 SEQ ID NO: 56, ORF= 1-3936 GCK NM_000162 SEQ ID NO: 19 SEQ ID NO: 20, ORF= 487-1884 MAP2K3 NM_002756 SEQ ID NO: 77 MAP2K6 NM_002758 NME4 NM_005009 SEQ ID NO: 1 SEQ ID NO: 2, ORF = 32-595 PANK1 NM_148977 SEQ ID NO: 78 PCK1 NM_002591 SEQ ID NO: 3 SEQ ID NO: 4 PFKL NM_002626 SEQ ID NO: 63 SEQ ID NO: 64, ORF = 60-2402 PIK4CA NM_058004 SEQ ID NO: 21 SEQ ID NO: 22, ORF = 1-6135 PRKCL2 NM_006256 PRKWNK3 NM_020922 SEQ ID NO: 5 SEQ ID NO: 6, ORF = 440-5842 PRPS1L1 NM_175886 SEQ ID NO: 79 PSKH1 NM_006742 SEQ ID NO: 57 SEQ ID NO: 58, ORF= 131-1405 -6- WO 2007/001928 PCT/US2006/023646 TABLE 1 Gene Acc. No. Amino acid Sequence Additional Information PTK9L NM_007284 SEQ ID NO: 80 SOCS5 NM_014011 SOCS5 N 014011 SEQ ID NO: 59 SEQ ID NO:60, ORF=165-1775 SRPK1 NM_003137 SRPK NM003137 SEQ ID NO: 17 SEQ ID NO: 18, ORF = 124-2091 STK16 NM_003691 SEQ ID NO: 7 SEQ ID NO: 8, ORF= 400-1317 STK35 NM 080836 SEQ ID NO: 81 SEQ ID NO: 28, ORF = 1-1206 TAF1 NM_004606 SEQ ID NO: 82 TBK1 NM_013254 SEQ ID NO: 83 TJP2 NM_004817 SEQ ID NO: 84 TNK1 NM 003985 SEQ ID NO: 61 SEQ ID NO: 62, ORF=117-2117 TPK1 NM 022445 SEQ ID NO: 85 TRIB3 NM_021158 SEQ ID NO: 86 TRPM7 NM_017672 SEQ ID NO: 87 VRK1 NM_003384 SEQ ID NO: 88 ALPPL2 NM 031313 SEQ ID NO: 89 SEQ ID NO: 24 AP4M1 NM_004722 SEQ ID NO: 23 CAPZA1 NM_006135 SEQ ID NO: 25 DNAH5 NM 001369 SEQ ID NO: 27 DOM3Z NM 005510 SEQ ID NO: 90 FTCD NM_006657 SEQ ID NO: 29 NM_206965 is provided by SEQ ID NO 30, ORF=45 1670 NM206965 NM_206965 is the predominant isoform, both isoforms are transcribed and make the same protein. The tested siRNAs should affect both isoforms. The difference between the two isoforms is in the 3'UTR PDIA3 NM_005313 SEQ ID NO: 31 SEQ ID NO: 32, ORF=149-1666 MDM4 NM_002393 SEQ ID NO: 91 SEQ ID NO: 26, ORF 163-1635 WDR66 NM 144668 SEQ ID NO: 92 NOP5/ NM_015934 SEQ ID NO: 33 SEQ ID NO: 34, ORF=151-1740 NOP58 NSUN6 NM 182543 SEQ ID NO: 93 PAFAH1B1 NM 000430 SEQ ID NO: 35 SEQ ID NO: 36, ORF=566-1788 PARVB NM_013327 SEQ ID NO: 94 ISOFORM B PARVB NM_001003828 SEQ ID NO: 37 SEQ ID NO: 38, ORF=53-1147 ISOFORM A PHEX NM_000444 SEQ ID NO: 39 SEQ ID NO: 40, ORF = 604-2853 PKN1 NM_002741 SEQ ID NO: 44 The siRNAs tested targeted both isoforms NM 213560 POLR2J2 NM_145325 ISOFORMI: ISOFORM 1 (NM145325) ORF=129-605: (SEQ ID NM032959 SEQ ID NO: 41 NO: 42) ISOFORM 3 (NM 032959) ORF=129-476: ISOFORM3: SEQ ID NO: 66 SEQ ID NO: 65 siRNAs were identified that targeted both NM_145325 and NM 032959. RAB20 NM_017817 SEQ ID NO: 43 -7- WO 2007/001928 PCT/US2006/023646 TABLE 1 Gene Acc. No. Amino acid Sequence Additional Information SYNPR NM_144642 SEQ ID NO: 45 SEQ ID NO: 46, ORF=99-896: TRPM5 NM 014555 SEQ ID NO: 47 SEQ ID NO: 48, ORF=10-3507 Nucleic acid and protein substantially similar to a particular identified sequence provide sequences with a small number of changes to the particular identified sequence. Substantially similar sequences include sequences containing one or more naturally occurring polymorphisms or artificial changes. A substantially similar protein sequence is at least 95% identical to a reference sequence. The substantially similar protein sequence should also not have significantly less activity than the reference sequence. Significantly less activity is less than about 80% activity of the identified protein. In different embodiments, the substantially similar protein sequence differs from the reference sequence by 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid alterations. Each-amino acid alteration is independently an addition, deletion or substitution. Preferred substantially similar sequences are naturally occurring variants. A substantially similar nucleic acid is at least 95% identical to a reference sequence. The substantially similar nucleic acid sequence should encode a protein that does not have significantly less activity than the protein encoded by the reference sequence. Significantly less activity is less than about 80% activity of the identified protein. Sequence identity to a reference nucleic acid sequence is determined by aligning the nucleic acid sequence with the reference sequence and determining the number of identical nucleotides in the corresponding regions. This number is divided by the total number of nucleotides in the reference sequence (e.g., SEQ ID NO: 2) and then multiplied by 100 and rounded to the nearest whole number. In different embodiments, the substantially similar nucleic acid sequence differs from the reference sequence by 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotide alterations. Each nucleic acid alteration is independently an addition, deletion or substitution. Preferred substantially similar sequences are naturally occurring variants. Protein Production Proteins can be produced using techniques well known in the art including those involving chemical synthesis and those involving purification from a cell producing the protein. Techniques for chemical synthesis of proteins are well known in the art. (See e.g., Vincent, Peptide and Protein Drug Delivery, New York, N.Y., Decker, 1990.) Techniques for recombinant protein production and purification are also well known in the art. (See for example, Ausubel, Current Protocols in Molecular Biology, John Wiley, 1987-2002.) -8- WO 2007/001928 PCT/US2006/023646 Obtaining a protein from a cell is facilitated using recombinant nucleic acid techniques to produce the protein. Recombinant nucleic acid techniques for producing a protein involve introducing, or producing, a recombinant gene encoding the protein in a cell and expressing the protein. A recombinant gene contains nucleic acid encoding a protein along with regulatory elements for protein expression. The recombinant gene can be present in a cellular genome or can be part of an expression vector. The regulatory elements that may be present as part of a recombinant gene include those naturally associated with the protein encoding sequence and exogenous regulatory elements not naturally associated with the protein encoding sequence. Exogenous regulatory elements such as an exogenous promoter can be useful for expressing a recombinant gene in a particular host or increasing the level of expression. Generally, the regulatory elements that are present in a recombinant gene include a transcriptional promoter, a ribosome binding site, a terminator, and an optionally present operator. A preferred element for processing in eukaryotic cells is a polyadenylation signal. Expression of a recombinant gene in a cell is facilitated through the use of an expression vector. Preferably, an expression vector in addition to a recombinant gene also contains an origin of replication for autonomous replication in a host cell, a selectable marker, a limited number of useful restriction enzyme sites, and a potential for high copy number. Examples of expression vectors are cloning vectors, modified cloning vectors, specifically designed plasmids and viruses. Due to the degeneracy of the genetic code, a large number of different encoding nucleic acid sequences can be used to code for a particular protein. The degeneracy of the genetic code arises because almost all amino acids are encoded by different combinations of nucleotide triplets or "codons". Amino acids are encoded by codons as follows: A=Ala=Alanine: codons GCA, GCC, GCG, GCU C=Cys=Cysteine: codons UGC, UGU D=Asp=Aspartic acid: codons GAC, GAU E=Glu=Glutamic acid: codons GAA, GAG F=Phe=Phenylalanine: codons UUC, UUU G=Gly=Glycine: codons GGA, GGC, GGG, GGU H=His=Hi-stidine: codons CAC, CAU I=Ile=Isoleucine: codons AUA, AUC, AUU K=Lys=Lysine: codons AAA, AAG L=Leu=Leucine: codons UUA, UUG, CUA, CUC, CUG, CUU M=Met=Methionine: codon AUG N=Asn=Asparagine: codons AAC, AAU P=Pro=Proline: codons CCA, CCC, CCG, CCU Q=Gln=Glutamine: codons CAA, CAG R=Arg=Arginine: codons AGA, AGG, CGA, CGC, CGG, CGU S=Ser=Serine: codons AGC, AGU, UCA, UCC, UCG, UCU -9- WO 2007/001928 PCT/US2006/023646 T=Thr=Threonine: codons ACA, ACC, ACG, ACU V=Val=Valine: codons GUA, GUC, GUG, GUU W=Trp=Tryptophan: codon UGG Y=Tyr=Tyrosine: codons UAC, UAU Techniques for recombinant gene production, introduction into a cell, and recombinant gene expression are well known in the art. Examples of such techniques are provided in references such as Ausubel, Current Protocols in Molecular Biology, John Wiley, 1987-2002, and Sambrook et al., Molecular Cloning, A Laboratory Manual, 2 nd Edition, Cold Spring Harbor Laboratory Press, 1989. If desired, expression in a particular host can be enhanced through codon optimization. Codon optimization includes use of more preferred codons. Techniques for codon optimization in different hosts are well known in the art. Identifying a Compound Inhibiting Binding to, or Activity or Expression of, a Target Protein The initial identification of a compound inhibiting binding to, or activity or expression of, a target protein can be determined experimental or based on available information concerning a target. Compounds binding to, or inhibiting protein activity, are directed at the protein. Compounds inhibiting protein expression are directed at nucleic acid encoding the protein or having a regulatory function. The ability of a compound to bind to a protein can be determined using techniques such as competitive and non-competitive binding assays. Such assays can be performed, for example, using a labeled compound to directly measure binding or measuring binding using a detectable reagent that binds to compound. Techniques for assaying kinase and phosphatase activity are well known in the art. For example, references describing techniques that can be used for measuring activity of NME4, PCK1, STK16, DUSP6, PIK4CA, PKWNK3, AKAP8, GCK, SRPK1, DGKD, DUT, GAK, PFKL, PSKH1, SOCS5, TNK1, DUSP19, and EPHA2 include: Kowluru et al., Arch. Biochem. Biophys., 398(2):160-169, 2002 (NME4); Mahoud et al., Biochemica Biophysica Acta, 1336:549-556, 1997 (PCK1); Ohta et al., Biochem J., 350 (Pt 2):395-404, 2000 (STK16); Kim et al., Biochemistry, 42(51):15197-207, 2003 (DUSP6); Varsanyi et al., Eur. J. Biochem., 179: 473-479, 1989 (PIK4CA); Xu et al., J. Biol. Chem. 275:16795-16801, 2000, (PRKWNK3); Akileswaran et al., J. Biol. Chem., 18:276(20):17448-54, 2001 (AKAP8); Van Schaftingen et al., Eur. J. Biochem., 179:179 -184, 1989 (GCK); Aubol et al., Proc. Natl. Acad. Sci., U S A., 100(22):12601-6, 2003 (SRPK1); Imai et al., J. Biol. Chem. 277(38):35323-32, 2002 (DGKD); Climie et al., Protein Express Purif 5(3):252-258 (1993) (DUT); Greener et al., J. Biol. Chem. 275(2):1365-1370, 2000 and Kimura et al., Genomics 44:179-187 (1997) (GAK); Furuya and Uyeda, J. Biol. Chem. 256(14):7109-7112, 1981, Hirada et al., Biosci. Biotechnol. Biochem. 64(10):2047-2052, 2000 (PFKL); Brede et al., Genomics 70(1): 82-92. 2000, Brede et al., Nucl. Acid Res. 30(23):5301 5309, 2002 (PSKH1); Kario et al., J. Biol Chem., 280 (8):7038-7048, 2005 (SOCS5); Felschow et al., Biochem. Biophys. Res. Comm. 273:294-301, 2000 (TNK1); Zama et al., J. Biol. Chem. 277(26):23909 23918, 2002; and Pratt et al., Oncogene 21(50):7690-9, 2002 (EPHA2). - 10- WO 2007/001928 PCT/US2006/023646 Inhibitors of different kinases and phosphatases are well known in art. Examples of such inhibitors include: 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one (KU-55933), which inhibits ATM (Hickson et al., Cancer Res., 64(24):9152-9, 2004); (5R,6S)-5-Azido-6-benzoyloxy-2-cyclohexen-1-one, which inhibits PIK4CA (Pelyvas et al., J. Med. Chem., 44: 627-632, 2001); 1-allyl-3-butyl-8 methylxanthine, which inhibits PCK1 (Foley et al., Bioorg. Med. Chem. Lett., 13(20):3607-10, 2003); 5 mercuri-dUTP and other UTP analogues that inhibit DUT (Climie et al., Protein Express Purif 5(3):252 258, 1993, Beck et al., Adv. Exp. Med. Biol., 195 Pt B (97-104), 1986; and N-bromoaceylethanolamine phosphate, which inhibits PFKL (Hirada et al., Biosci. Biotechnol. Biochem. 64(10):2047-2052, 2000). Techniques that can be used for assaying the enzymatic activity and/or compound binding for the non-kinase target proteins described in Table 1 are also known. Examples of references describing techniques for activity assays that can be used for measuring TRPM5, PHEX, MDM4, PDIA3, APPL2, and PARVB include: Prawitt et al., Proc Natl Acad Sci USA, 100:15166-15171, 2003 (TRPM5); Boileau et al., Biochem J. 355:707-713, 2001 (PHEX); Badciong and Haas, J. Biol. Chem., 277:49668 49775, 2002 (MDM4); Frickel et al., J. Biol. Chem., 279:18277-18287, 2004, (PDIA3); Hoylaerts et al., Biochem. J. 277:49808-49814, 1992 (ALPPL2); Olski et al., J. Cell Sci. 114:525-538 (2000) (PARVB). Although PAFAH1B 1 is the catalytically inactive subunit of platelet activating factor acetylhydrolase, assay conditions for the full acetylhydrolase enzyme complex can be found in Hattori and Inoue, J. Biol. Chem. 268:18748-18753, 1993 (PAFAH1B 1). The encoding nucleic acid sequence of an identified protein provides a target for compounds able to hybridize to the nucleic acid. Examples of compounds able to hybridize to a nucleic acid sequence include siRNA, ribozymes, and antisense nucleic acid. The mechanism of inhibition varies depending upon the type of compound. Techniques for producing and using sRNAi, ribozymes, and antisense nucleic acid are well known in the art. (E.g., Probst, Methods 22:271-281, 2000; Zhang et al., Methods in Molecular Medicine Vol. 106: Antisense Therapeutics 2 nd Edition, p. 11-34, Edited by I. Philips, Humana Press Inc., Totowa, NJ, 2005.) In addition, the examples provided below illustrate the use of siRNA. Vector for delivering nucleic acid based compounds include plasmid and viral based vectors. Preferred vectors for therapeutic applications are retroviral and adenovirus based vectors. (Devroe et al., Expert Opin. Biol. Ther. 4(3):319-327, 2004, Zhang et al., Virology 320:135-143, 2004.) Measuring HCV Inhibitory Activity The ability of a compound to inhibit HCV replication can be measured in vitro or using animal models. (Pietschmann et al., Clin Liver Dis. 7(1):23-43, 2003.) In vitro techniques for measuring the ability of a compound to inhibit HCV replication involve using HCV or an HCV replicon. Because HCV is difficult to grow in culture, preferred in vitro techniques employ an HCV replicon. An HCV replicon is an RNA molecule able to autonomously replicate in a cultured cell, such as Huh7. The HCV replicon expresses the HCV derived components of the replication machinery and contains cis-elements required for replication in a cultured cell. -11- WO 2007/001928 PCT/US2006/023646 The production and use of HCV replicons are described in different references. (See, for example, Lohmann et al., Science, 285:110-113, 1999; Blight et al., Science, 290:1972-1974, 2000; Lohmann et al., Journal of Virology, 75:1437-1449, 2001; Pietschmann et al., Journal of Virology, 75:1252-1264, 2001; Grobler et al., J. Biol. Chem., 278:16741-16746, 2003; Murray et al., J. Virol., 77(5):2928-2935, 2003; Zuck et al., Anal. Briochem.334(2):344-355, 2004; Ludmerer et al., Antimicrob. Agents Chemother,. 49(5):2059-69, 2005; Rice et al., International Publication Number WO 01/89364, published November 29, 2001; Bichko, International Publication Number WO 02/238793, published May 16, 2002; Kukolj et al., International Publication Number WO 02/052015, published July 4, 2002; De Francesco et al., International Publication Number WO 02/059321, published August 1, 2002; Glober et al., International Publication Number WO 04/074507, published September 2, 2004; and Bartenschlager U.S. Patent No. 6,630,343.) The ability of a compound to inhibit HCV replication can be measured in naturally occurring or artificial animal models susceptible to HCV infection. Only a few animals such as humans and chimpanzees are susceptible to HCV infection. Chimpanzees have been used as animal models for determining the effect of a compound on HCV infection. Artificial animal models susceptible to HCV infection have been produced by transplanting human livers cells into a mouse. (Pietschmann et al., Clin Liver Dis., 7(1):23-43, 2003.) The use of transgenic mice with chimeric mouse-human livers provides for a small animal model. Measuring HIV Inhibitory Activity The ability of a compound to inhibit HIV replication can be measured in vitro or using animal models. In vitro techniques for measuring the ability of a compound to inhibit HIV replication include, for example, techniques measuring early steps in the viral life cycle (entry through integration). or involve using HIV infection of T-cell lines, or peripheral blood mononuclear cells to follow a spreading viral infection. (E.g., Joyce et al., J. Biol. Chem. 277(48):45811-20, 2002; Nunberg et al., J. Virol 65(9): 4887-4892, 1991; Goldman et al., Antimicrob Agents Chemother. 36(5):1019-1023, 1992.) The ability of a compound to inhibit HIV replication can be measured in non-human primate models susceptible to infection with either HIV; or a chimeric virus created by combining fragments of the HIV and SIV (simian immunodeficiency virus) genome, termed a SHIV (simian-human immunodeficiency virus). Only a few animals such as humans and chimpanzees are susceptible to HIV infection. Chimpanzees have been used as animal models for determining the effect of a compound on HIV infection. (Grob et al., Nat Med. 3(6):665-670, 1997.) More frequently, determining the effect of a compound on HIV infection in non-human primates is carried out in rhesus macaques infected with SHIV. (Hazuda et al., Science 305(5683):528-32, 2004.) Administration Guidelines for pharmaceutical administration of a therapeutic compound in general are provided in, for example, Remington's Pharmaceutical Sciences 20 th Edition, Ed. Gennaro, Mack - 12 - WO 2007/001928 PCT/US2006/023646 Publishing, 2000; and Modern Pharmaceutics 2 nd Edition, Eds. Banker and Rhodes, Marcel Dekker, Inc., 1990. Compounds active at a therapeutic target having appropriate functional groups can be prepared as acidic or base salts. Pharmaceutically acceptable salts (in the form of water- or oil-soluble or dispersible products) include conventional non-toxic salts or the quaternary ammonium salts that are formed, e.g., from inorganic or organic acids or bases. Examples of such salts include acid addition salts such as acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2 naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, and undecanoate; and base salts such as ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D glucamine, and salts with amino acids such as arginine and lysine. Compounds can be administered using different routes including oral, nasal, by injection, transdermal, and transmucosally. Active ingredients to be administered orally as a suspension can be prepared according to techniques well known in the art of pharmaceutical formulation and may contain microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners/flavoring agents. As immediate release tablets, these compositions may contain microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants. When administered by nasal aerosol, or inhalation, compositions can be prepared according to techniques well known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents. The compounds may also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous, topical with or without occlusion, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts. When administered by injection, the injectable solutions or suspensions may be formulated using suitable non-toxic, parenterally-acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution or isotonic sodium chloride solution, or suitable dispersing or wetting and suspending agents, such as sterile, bland, fixed oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid. When rectally administered in the form of suppositories, compositions may be prepared by mixing the drug with a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquidify and/or dissolve in the rectal cavity to release the drug. - 13 - WO 2007/001928 PCT/US2006/023646 Suitable dosing regimens for the therapeutic applications of the present invention are selected taking into account factors well known in the art including age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound employed. Guidelines for pharmaceutical administration and pharmaceutical compositions are provided in, for example, Remington's Pharmaceutical Sciences 20' h Edition, supra. and Modern Pharmaceutics 2 nd Edition, supra. Optimal precision in achieving concentrations of drug within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the drug's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a drug. The daily dose for a patient is expected to be between 0.01 and 1,000 mg per adult patient per day. Examples Examples are provided below further illustrating different features of the present invention. The examples also illustrate useful methodology for practicing the invention. The examples do not limit the claimed invention. Example 1: Screening the Protein Kinase and Phosphatase siRNA library Potential host cell factor targets for inhibiting HCV replicon replication were identified using an HCV Conl-lb -lactamase-expressing replicon expressed in Huh-7 cells and a siRNA library targeting host siRNA. The procedure was performed as follows: Day 1: Plate HuH-7 cells expressing a tissue culture-adapted HCV Conl-lb P-lactamase-expressing replicon (Zuck et al., Anal. Biochem., 334(2):344-355, 2004), at 2000 cells/well in black, clear-bottom 96-well plates (Costar, cat # 3603). Plate cells in 100 pL DMEM (Invitrogen, 21063-029), 10% Fetal bovine serum (Invitrogen 16140-071), 1X Non-essential amino acids (Invitrogen, 11140-050), 1X Glutamax (Invitrogen, 35050-061). Allow cells to attach and grow overnight at 37 0 C, 5% CO2. Day 2: Transfect plated HuH-7/replicon cells as follows: 1. Resuspend siRNA by adding 200 tL of 1X buffer (Dharmacon) to each well, producing a final siRNA concentration of 10 pM. Control siRNAs: (+ control) HCV siRNA (Randall et al., Virus Res. 102(1):19-25, 2004) AACCUCAAAGAAAAACCAACdTdT (SEQ ID NO: 95) (+ control) HVAP33 siRNA (TGI) CUGUUCCACUGAAUGCAUCdTdT (SEQ ID NO: 96) (TGI) AUCGGCACCUGAGAGAUGAdTdT (SEQ ID NO: 96) - 14- WO 2007/001928 PCT/US2006/023646 (Zhang et al., Virology. 320(1):135-143, 2004) GAUGGACCUAUGCCAAAACdTdT (SEQ ID NO: 97) (- control) NS 1 siRNA (Dharmacon) Use controls at 10 RtM as well. The final concentration of siRNA added to the cells will be 50 nM. 2. Dispense 33 gL of Optimem/well into a sterile 96-well plate, leaving the 12 column empty. 3. Transfer 1 pL of siRNA from each well of the siRNA stock plate into the Optimem-containing plates such that the siRNA from well A3 of the mother plate is transferred into well A2 of the daughter plate (1 pL of siRNA from each well is transferred into the corresponding plate into the same row position and the N-1 column position). 4. Mix by pipetting up and down. 5. In a tube, add 100 pL Oligofectamine (Invitrogen, 12252-011), 1210 tL Optimem Reduced Serum Media (Invitrogen, 11058-021). Incubate 5 minutes at room temperature. 6. Dispense 6 gL of the Oligofectamine to each well and mix by pipetting up and down. Incubate the plate at room temperature for 15 minutes. 7. Remove media from the cells and replace with 80 L (DMEM (phenol red free), 1X Non essential amino acids, 1X Glutamax). Add 20 PL of the siRNA/Oligofectamine mixture to each corresponding well. 8. Incubate the plate at 37 0 C, 5% CO 2 for 4 hours. 9. Add 50 gL of DMEM (phenol red free) + 30% Fetal bovine serum, IX Non-essential amino acids, 1X Glutamax. Incubate the cells at 37 0 C, 5% CO 2 for 48 hours. 10. Remove media from cells and replace with 100 gL/ well DMEM (phenol red free), 10% FBS, 1X non-essential amino acids, 1X Glutamax and 0.5 pM Clavulanic acid. Incubate cells at 37 0 C, 5% CO2 for 24 hours. 11. Remove media from cells and replace with 50 pL of the following solution: 12 mL DMEM (phenol red-free), 24 pL CCF4 (1 mM solution in DMSO), 2 mL Solution C (Aurora), 120 PL Solution B (Pluronic Acid, Aurora). 12. Incubate cells in the dark at room temperature for 1.5 hours. 13. Read the plates at 460 nm and 530 nm using a plate reader capable of reading fluorescence intensity. 14. Data analysis: Determine an average background for both A460 and A538 (average of counts from column 12). Subtract background from each well. Divide A460 by A538 after background subtraction to determine blue/green ratio for each cell. Calculate average and standard deviation for each transfection. - 15- WO 2007/001928 PCT/US2006/023646 This analysis was carried out in duplicate for each plate of the Dharmacon Kinase and Phosphatase siRNA libraries. Hits were considered to be those siRNA that suppressed replication of the replicon by 40% or more, as measured by 3-lactamase activity (A460/A530 ratio compared with NS 1 siRNA-transfected control) and did not inhibit cell viability by more than 20% as measured by the A530 reading compared with NS1 siRNA-transfected control. Results: Eighty-nine hits were identified in the primary screen: AKAP8, ALK, ASP, ATM, C140RF24, CSNK1E, CSNK2A1, CSNK2B, CXCL10, DDR1, DGKD, DGKG, DGKZ, DLG2, DUSP18, DUSP19, DUSP22, DUSP5, DUSP6, DUT, DYRK2, DYRK4, EGFR, ENPP5, EPHA2, EPHA3, FBP2, FGFR2, FGFR4, FHIT, FLJ20442, FLJ35107, FN3K, FRK, GAK, GCK, HIPK3, HK3, I 4, IGBP1, IMPK, LOC339221, LPPR4, MAP2K3, MAP2K6, MAP3K1, MAP3K7IP1, MGC1136, MTMR1, MTMR7, NME4, PANK1, PCK1, PCK2, PCTK1, PFKL, PIK4CA, PHKA2, PHKG2, PPAP2C, PPP1R11, PPP1R2, PRKCL2, PRKD2, PRKWNK3, PRKY, PRPS1, PRPS1L1, PRPSAP1, PSKH1, PTK2B, PTK9L, PTP4A3, PTPN2,,RIPK2, SOCS5, SRPK1, STK16, STK3, STK33, STK35, STK38, TAF1, TBK1, TJP2, TNK1, TPK1, TRPM7, TXK, ULK2, and VRK1. Example 2: Counter Screening the Hits for Liver Expression using the Body Atlas Since HCV replicates in the liver, one requirement for host HCV targets is that the gene is expressed in the liver. The gene expression for the 89 genes described in Example 1 in different tissues were evaluated using a previously generated Body Atlas. The Body Atlas provides the relative gene expression for different genes in different tissues compared to expression of an mRNA pool from multiple tissues. Genes were considered to have liver high expression if the relative expression level was greater than 1.5 relative intensity, medium expression if the gene was between 0.5 and 1.5 relative intensity, and low expression if the gene was between 0.05 and 0.5 relative intensity. Genes with less than 0.05 relative intensity were not considered to be expressed in the liver. Genes eliminated from further consideration as targets included those not expressed in liver and those with low level liver expression that were only identified as hits in one of the two replicate screens. The genes that were not expressed in liver included: ASP, FBP2, I-4, LPPR4, MTMR7, PRP4A3, and STK33. These genes were considered to be false positives or genes that were essential for maintenance of the replicon in cultured cells only. Genes with moderate to high levels of expression within the liver were selected for further analysis. Genes with low level liver expression were only selected for further analysis if they inhibited HCV replication in each of the two times the library was screened. Genes with low level liver expression that were not chosen for further analysis included CSNK1E, DGKG, DLG2, DUSP5, MAP3K1, MAP3K71P1, PCTK1, PTK2B, RIPK2, and STK38. -16- WO 2007/001928 PCT/US2006/023646 Table 2 provides a list of the targeted genes chosen for further analysis and an indication of their relative level of expression in liver: TABLE 2 Liver Expression Gene Name Level High IMPK, FGFR4, FRK, PANK1, PCK1, PCK2, PFKL Moderate C140RF24, CXCL10, DUSP6, EGFR, EPHA3, FGFR2, FHIT, DUSP23, FLJ35107, FN3K, GAK, GCK, ENPP7, MAP2K3, MAP2K6, NME4, PHKA2, PHKG2, PPAP2C, PPP1R11, PRKD2, PRKWNK3, PRKY, PRPS1, PRPS1L1, PRPSAP1, PSKH1, STK16, TAF1, TBK1, TJP2, TNKl, TRPM7, TXK Low AKAP8, ALK, ATM, CSNK2A1, CSNK2B, DDR1, DGKD, DGKZ, DUSP18, DUSP19, DUSP22, DUT, DYRK2, DYRK4, ENPP5, EPHA2, HIPK3, HK3, IGBP1, MGC1136, MTMR1, PIK4CA, PPP1R2, PRKCL2, PTK9L, PTPN2, SOCS5, SRPK1, STK3, STK35, TPK1, ULK2, VRK1 Example 3: Confirmation of siRNA Hits From the primary screen of the kinase and phosphatase library, 80 siRNA pools were selected that both suppressed the HCV replicon and also were expressed in liver. siRNA pools were designed to have four siRNAs directed against the same gene in each well of the pool plate. To confirm the hits, each of the four siRNAs in the pool were tested individually in an 8-point, 2-fold titration. Confirmed hits were expected to demonstrate titrateable inhibition with at least two of the individual siRNAs present in the pool (since it is highly unlikely that two distinct siRNA sequences would have the same off-target effect). DAY 1: Reagents and Consumables: CM.10 Cells Trypsin (Invitrogen) DMEM Plating Media: DMEM (Invitrogen), 10% FBS (Invitrogen), IX GlutaMax (Invitrogen), 1X Non-Essential Amino Acids (Invitrogen) Trypan Blue (Invitrogen) 96-well Cell Plate (Coming) Procedure: 1. Trypsinize a flask of CM.10 cells. 2. Inactivate the Trypsin by adding DMEM Plating Media to the flask. 3. Remove a 10 ul aliquot of the cell suspension and dilute it 1:2 in Trypan Blue for viability staining. 4. Count the cells using a hemocytometer. - 17- WO 2007/001928 PCT/US2006/023646 5. Dilute the cells in DMEM Plating Media to a final concentration of 20,000 cells/ml. 6. Plate the cells at a density of 2000 cells/well by adding 100 ul of the cell suspension [20,000 cells/nl] to columns 1-11 of a 96-well Cell Plate. 7. Incubate the 96-well Cell Plate under normal growth conditions (37 oC, 5% CO 2 ) for 18-20 hours. DAY 2 Reagents and Consumables: siRNA Master Plate Oligofectamine (Invitrogen) Optimem-I (Invitrogen) DMEM Transfection Media: DMEM (Invitrogen), 1X GlutaMax (Invitrogen), 1X Non-Essential Amino Acids (Invitrogen) 96-well Titration Plate (Corning) Procedure: 1. Add Optimem-I to the 96-well Titration Plate (Duplicate eight times). The Titration plate can be set up in a grid with columns numbered 1-12 and rows A-H. Column 1, rows A-H gets 33 ul: Columns 2-11 row A gets 66 ul; columns 2-11, rows B-H gets 34 ul; and column 12 is kept empty. 2. A 96-well Master Plate is set up in a grid with columns numbered 1-12 and rows A-H. Column 1, rows A-H is a control; Columns 2-11 rows A-H are sample; and column 11 is empty. 3. Transfer 2 uL of siRNA [10 uM] (Samples) from the wells in Row A, Columns 2-11 of the Master Plate to the wells in Row A, Columns 2-11 of the 96-well Titration Plate. 4. Transfer 1 uL of siRNA [10 uM) (Controls) from the wells in Column 1 of the Master Plate to the wells in Column 1 of the 96-well Titration Plate. 5. Mix the samples by pipetting up and down gently. 6. Perform an 8-point, 2-fold serial dilution of the siRNA (Sample) by transferring and mixing 34 uL of sample from the wells in Row A, Columns 2-11 to the wells in Row B, Columns 2-11. Continue the titration by transferring and mixing 34 uL of sample from Row C to D, D to E, E to F, etc. The final concentration of siRNA at each titration point will be 50 nM, 25 nM, 12.5 nM, 6.25 nM, 3.125 nM, 1.5625 nM, 0.78125 nM and 0.390625 nM. Repeat the plate setup and titration setup eight times to account for all eight rows of samples from the Master plate. 7. In a 15 mL conical tube, add 5.50 mL of Optimem-I and 0.50 mL of Oligofectamine. Mix gently. 8. Incubate the mixture for 5 minutes at room temperature. 9. Add 6 uL of the Oligofectamine mixture to each well of the 96-well Titration Plate, containing siRNA. Mix gently. - 18- WO 2007/001928 PCT/US2006/023646 10. Incubate the siRNA:Oligofectamine mixtures for 15 minutes at room temperature to form the transfection complexes. 11. During the siRNA:Oligofectamine incubation, remove the media from the cells in the 96-well Cell Plate with a multi-channel pipettor. 12. Replace the media with 50 uL of DMEM Transfection Media. 13. After the 15 minutes needed for the siRNA:Oligofectamine complex formation has expired, transfer 20 uL of complex from the 96-well Titration Plate to the matching wells on the 96-well Cell Plate. The final concentration of siRNA at each titration point will be 50 nM, 25 nM, 12.5 nM, 6.25 nM, 3.125 nM, 1.5625 nM, 0.78125 nM and 0.390625 nM. 14. Incubate the 96-well Cell Plate under normal growth conditions (37 0 C, 5% C0 2 ) for 4 hours. 15. After the 4-hour incubation time has expired, add 30 uL of DMEM FBS Media to each of the wells containing cells and transfection mixes on the 96-well Cell Plate. 16. Incubate the 96-well Cell Plate under normal growth conditions (37oC, 5% CO 2 ) for 48 hours. DAY 4 Reagents and Consumables: Clavulanic Acid DMEM Plating Media: DMEM (Invitrogen), 10% FBS (Invitrogen), 1X GlutaMax (Invitrogen), 1X Non Essential Amino Acids (Invitrogen) Procedure: 1. Remove the media from the wells on the 96-well Cell Plates. 2. Add 100 uL of DMEM Plating Media; 0.5 uM Clavulanic Acid. 3. Incubate the 96-well Cell Plate under normal growth conditions (37 0 C, 5% CO 2 ) for 24 hours. DAY 5 Reagents and Consumables: DMEM Staining Media: DMEM (Invitrogen) 1 M HEPES CCF4 Solution B (Aurora, CET338P41), Solution C (Aurora, CET338P39), Procedure: 1. Prepare the staining solution as follows (sufficient amount for eight plates): a. 72 mL of DMEM Staining Media; 25 mM HEPES b. 0.144mLofCCF4 [1 mM - 19.- WO 2007/001928 PCT/US2006/023646 c. 0.720 mL of Solution B d. 12 ml of Solution C 2. Remove the media from the wells on the 96-well Cell Plates. 3. Add 50 uL of staining solution to all of the wells on the 96-well Cell Plates, including the wells in Column 12. 4. Incubate the plates at room temperature in the dark for 1.5 hours. 5. Read fluorescence intensity at A460 and A530 Data Analysis: Subtract background (no cell wells) from each sample reading. Calculate the A460/A530 ratio. Normalize as a percentage of Nonsilencing control siRNA. Graph the data for each siRNA as % of control A460/A530 vs. Concentration of siRNA transfected. For an siRNA to be considered validated, at least two of the four siRNAs tested inhibited HCV replication by at least 40% to 60% of control levels and the inhibition should titrate with decreasing amounts of transfected siRNA. Genes that were validated as essential for maintenance of the HCV replicon using the above criteria were then categorized into four groups, with priority 1 having the most desirable criteria for a HCV target. Gene classification was determined as follows: Priority 1: The most potent siRNA resulted in > 70% inhibition of HCV replicon replication. Moderate to high expression in Liver. These genes and encoded proteins are the preferred targets for inhibiting HCV infection. Priority 2: The most potent siRNA resulted in > 60% inhibition of HCV replicon replication. Any level liver expression. Priority 3: The most potent siRNA resulted in between 60 and 50% inhibition of HCV replicon replication. Priority 4: The most potent siRNA resulted in between 50 and 40% inhibition of HCV replicon replication. Genes essential for HCV replicon replication and their designated categories are shown in Table 3. TABLE 3 Priority Gene 1 NME4, PCK1, PRKWNK3, STK16, DUSP6 2 SOCS5, SRPK1, DGKD, DGKZ, ENPP5, EPHA2, GAK, GCK, PANK1, PFKL, PIK4CA, PTK9L, STK35, TAF1, FHIT, AKAP8 - 20 - WO 2007/001928 PCT/US2006/023646 CSNK2B, DYRK2, DYRK4, MAP2K3, MAP2K6, PRPS1L1, PSKH1, TBK1, TJP2, TRPM7, VRK1, DUSP19 ALK, ATM, CSNK2A1, DDR1, FGFR2, FRK, PRKCL2, TNK1, TPK1, TRIB3, 4 C140RF24, DUSP22, DUT Example 4: Screening of a Genome-Scale siRNA library Screening of a library of over 22,000 siRNA pools was carried out essentially using the methods described in example 1. Briefly, HuH-7 cells containing the HCV con1-lb replicon expressing beta-lactamase (CM. 10) were plated onto 384-well plates. The following day the cells were transfected with an array of siRNA pools including control siRNAs using Oligofectamine according to the manufacturer's directions. 72 hours after transfection, the cells were stained for beta-lactamase expression using CCF4, according to the manufacturer's instructions. Unlike in example 1, clavulanic acid was not added to the cells. 640 siRNA pools that affected beta-lactamase expression were then assayed an additional three times to confirm their effect on HCV replication. 39 siRNA pools were then selected for further confirmation. Six individual siRNAs targeting each of the genes targeted by the 39 siRNA pools were transfected separately into CM. 10 cells and assayed as above. Effective inhibition of HCV replication by a minimum of two siRNAs targeting one of the tested genes was considered to be confirmation of the importance of the host factor for HCV coni lb replication. Results: Nineteen genes were confirmed in this screen, including: ALPPL2, AP4M1, CAPZA1, DNAH5, DOM3Z, FTCD, PDIA3, MDM4, WDR66, NOP5/NOP58, NSUN6, PAFAH1B 1, PARVB, PHEX, PKN, POLR2J2, RAB20, SYNPR, and TRPM5. All of the confirmed siRNA pools targeted genes that had at least low levels of liver expression. Example 5: Screening of Hits Using a Chimeric BK:2b(NS5b) Replicon An experiment was performed to determine whether a chimeric BK:2b(NS5b) replicon is sensitive to knock-down of the same genes as the ConI lb replicon. The employed procedure is described in Examples 1 and 4, except a BK replicon containing a genotype 2b NS5b sequence was used. The BK:2b(NS5b) replicon is described by Grobler et al., J. Biol. Chem., 278:16741-16746, 2003. Data analysis was carried for each confirmed siRNA hit. The effects of siRNA transfection on the BK:2b(NS5b) replicon are shown in Table 4: -21- WO 2007/001928 PCT/US2006/023646 TABLE 4 Activity in BK:2b(NS5b) Gene Replicon SRPK1, EPHA1, TNK1, STKl6, DYRK4, EPHA2, MAP2K6, PRPSL1, >39% inhibition NME4, DGKD, TPK1, PRKWNK3, GCK, PIK4CA, FTCD TRPM7, PFKL, ALK, CSNK2B, FHIT, PTK9L, FGFR2, DUSPl9, DUT, 20-39% inhibition DGKZ, TJP2, PRKCL2, DDR1, DUSP22, SOCS5, SYNPR, POLR2J2, ALPPL2, NOP5/NOP58, AKAP8, C14orf20, TBK1, MAP2K3, GAK, ATM, FRK, PANK1, No effect PSKH1, DYRK2, CSNK2A1, TAF1, RAB20, TRPM5, WDR66, NSUN6, DNAH5, PARVB, AP4M1, PAFAH1B1, DOM3Z, PHEX, CAPZA1 Increased BK lb STK35 STK35 replication 1 Example 6: Activity against HCV Genotype la, Con-lb and 2a Replicons A quantitative, multiplex TaqMan assay was established to measure the relative quantities of HCV Replicon RNA in three HCV Replicon cell lines, Con-lb, la and 2a. Briefly, total RNA was isolated from replicon cells transfected with siRNAs using the RNeasy 96-well Kit (Qiagen, #74182). TaqMan reactions utilized the TaqMan EZ RT-PCR Kit (Applied Biosystems, #403028), TaqMan PDAR Control Reagent Human Cyclophilin A (Applied Biosystems, #4310883E) as well as a probe and primer set targeting the neomycin resistance gene of the HCV Replicon genome (Neo fwd: SEQ ID NO: 98; Neorev: SEQ ID NO: 99; and Neoprobe 5' FAM-SEQ ID NO: 100-TAMRA 3'). The final concentration of each component in the reaction mixture was as follow: 1X TaqMan EZ Buffer, 3 mM Mn(Oac)2, 0.3 mM dATP, 0.3 mM dCTP, 0.3 mM dGTP, 0.6 mM dUTP, 0.2 mM Forward Primer, 0.2 mM Reverse Primer, 0.1 mM Probe, IX PDAR Cyclophilin A Mix, 0.1 Unit/p l rTth DNA Polymerase, 0.01 Unit/pl AmpErase UNG, 10 pl of total RNA and H20 to 50 pl. The 96-tube optical plate (Applied Biosystems #N801-0560) was covered with an optical adhesive cover (Applied Biosystems, #4311971) and mixed by inverting several times. The samples were placed in an ABI 7700 (Applied Biosystems) for multiplex TaqMan analysis by setting the entire plate to the FAM dye layer for "unknowns" (HCV) and to the VIC dye layer for the Endogenous control, Cyclophilin A. The cycling parameters were set to 50 0 C, 2 min.; 60 0 C, 30 min.; 95 0 C, 5 min.; (94 0 C, 20 sec.; 55 0 C, 1 min.) 40 cycles, utilizing spectral compensation and an exposure time of 10 milliseconds. To calculate the relative quantities of each target RNA in the samples, a standard curve was generated for the HCV Neo primer and probe sets as well as the endogenous control, Cyclophilin A Pre-Developed Assay Reagent (PDAR) in each of the three HCV Replicon cell lines. Total RNA was isolated from the Replicons using the RNeasy Mini Kit (Qiagen, # 74104) following the manufacturer's protocol. The TaqMan Cycle Threshold (Ct) values was determined for a 7-point, five-fold titration of the total RNA. The natural log of the mass (ng) of total RNA was determined and plotted over the Ct values. The equation of the line for each probe and primer set in each of the HCV replicon cell lines was calculated to derive the relative quantity of the HCV RNA and the endogenous control, Cyclophilin A -22 - WO 2007/001928 PCT/US2006/023646 mRNA, from their respective Ct values. HCV RNA levels were normalized to the endogenous control, Cyclophilin A, mRNA levels. Results Priority 1 targets: siRNAs inhibited replication of HCV genotype la, Con-lb , and 2a replicons by greater than 30%: DUSP19, DUT, DYRK4, GAK, PARVB, PFKL, PIK4CA, PSKH1, SOCS5, SYNPR, and TRPM5. Priority 2 targets: siRNAs inhibited replication of two HCV genotypes by at least 50%: PAFAH1B1, STK16, and TNK1. Priority 3 targets: siRNAs inhibited replication of two HCV genotypes by at least 30%: AKAP8, ALK, AP4M1, CAPZA1, DGKD, DNAH5, DYRK2, EPHA2, FGFR2, FRK, FTCD, GCK, NOP5/NOP58, PDIA3, PHEX, POLR2J2, PRKWNK3, RAB20, STK35, TJP2, TPK1, TRIB3, and TRPM7. Priority 4 targets: siRNAs inhibited replication of one HCV genotype by at least 30%: ALPPL2, CSNK2A1, CSNK2B, DDR1, DGKZ, DOM3Z, DUSP22, DUSP6, MAP2K6, NME4, PCK1, PRPS1L1, PTK9L, SRPK1, TAF1, TBK1, VRK1, and WDR66. Example 7: Inhibition of HCV lb Subgenomic Replication in HeLa Cells The ability of Priority 1 targets to inhibit HCV lb subgenomic replication in a replicon clone engineered to replicate in HeLa cells was tested. Inhibition of subgenomic replication in HeLa cells serves as evidence that the requirement for the target gene is not an artifact of the HuH-7 cell line. The HCV HeLa replication system was as described in Zhu et al., J. Virol, 77(17):9204-9210, 2003. siRNA transfection and quantification of subgenomic replication were carried out as described in Example 6. Results: The priority 1 targets DUT, GAK, PFKL, PIK4CA, PSKH1, and SYNPR inhibited HCV con lb subgenomic replication in HeLa cells by at least 30%. PARVB, SOCS5, and TRPM5 siRNAs were toxic in these cells and effects on HCV replication could not be assessed. DUSPl9 and DYRK 4 siRNAs were ineffective against HCV subgenomic replication in HeLa cells. Example 8: Inhibition of HCV Replication with Wortmannin PIK4CA has two reported isoforms. Isoform 1 (mRNA: NM_002650, protein: NP 002641) is shorter and lacks much of the N-terminal portion of the Isoform 2 (mRNA: NM_058004, protein: NP_477352) protein. PIK4CA isoform 1 has been characterized as a type II phosphatidylinositol 4-kinase, which is sensitive to adenosine and insensitive to wortmannin (Wong and Cantley, J. Biol. Chem., 269:28878-28884, 1994), while PIK4CA isoform 2 has been characterized as a - 23 - WO 2007/001928 PCT/US2006/023646 type III phosphatidylinositol 4-kinase, which is sensitive to wortmannin and insensitive to adenosine (Gehrmann et al., Biochim. Biophys. Acta, 1437:341-356, 1999). To ascertain whether isoform 2 was the relevant isoform for HCV replication, we tested the effect of the kinase inhibitor, wortmannin, which inhibits type II phosphatidylinositol 4-kinases in cells at micromolar levels, on HCV replication. Briefly, the beta-lactamase expressing, HCV Conl-b CM10 cell line was plated at 7500 cells/well in 50 ul of cell Complete Media (DMEM, 10% FBS, lx NEAA, lx Glutamax, (-) Pen/Strep) on 96-well Black Tissue Culture Treated Plate. A 10 mM DMSO stock of wortmannin (Sigma, #W1628) was diluted to 100 gM in 200 jtl of Complete Media and titrated over a seven point, 2.5-fold dilution series. Fifty (50) pl from each of the dilution points was transferred to the assay plate containing the HCV Con 1-b CM10 cells to produce the following concentrations of wortmannin [gM]: 50, 20, 8, 3.2, 1.28, 0.512 and 0.2048. The cells were incubated at 37 0 C, 5% CO 2 for 24 hours. To inhibit endogenous 8-lactamase activity in the HCV Conl-b CM10 cell line, a 1 mM DMSO stock of Clavulanic acid (US Pharmocopeia, #1134426) was diluted to 5.5 gM in Complete Media of which 10 pl was added to the cells to produce a final concentration of 0.5 tM. The cells were incubated at 37 0 C, 5%CO2 for 24 hours. To measure the B-lactamase activity in the HCV Conl1-b CM10 cell line, the GeneBlazer B-lactamase (Invitrogen, #K1085) stain mixture was prepared based on the manufacturer's protocol. The cell culture/compound media was removed from the cells and replaced with 50 pl of the GeneBlazer B lactamase stain mixture. The cells were incubated in the dark at room temperature for 1.5-2.0 hours. The A460 and A530 fluorescence intensities at were measured on an LJL Analyst. Results: Wortmannin inhibited HCV replication with an ICs 0 of 7.1 pM. The data is consistent with HCV replication having a requirement for PIK4CA function. Example 9: siRNAs Specifically Targeting PIK4CA Isoform 2 Disrupt HCV Replication To demonstrate the requirement for PIK4CA isoform 2 in HCV replication, siRNAs targeting isoform 2 mRNA only (NM058004) were tested for inhibition of HCV replication. The following siRNAs were transfected into CM. 10 cells and tested for inhibition of HCV subgenomic replication as described in Example 1: PIK4CA2-1: sense 5' UCAACGGUUCACAUAUAAdTdT 3' (SEQ ID NO: 101) Antisense 5' UUAUAUGUGACACCGUUGAdTdT 3' (SEQ ID NO: 102) PIK4CA2-2: sense 5' GGUCCGUCCUCCAGUAUAAdTdT 3' (SEQ ID NO: 103) Antisense 5' UUAUACUGGAGGACGGACCdTdT 3' (SEQ ID NO: 104) PIK4CA2-3 sense 5' CAGACCGGAUCCACAAUGAdTdT 3' (SEQ ID NO: 105) Antisense 5' UCAUUGUGGAUCCGGUCUGdTdT 3' (SEQ ID NO: 106) PIK4CA2-4 sense 5' GGAGUACUCAUUCCUGUAAdTdT 3' (SEQ ID NO: 107) -24- WO 2007/001928 PCT/US2006/023646 Antisense 5' UUACAGGAAUGAGUACUCCdTdT 3' (SEQ ID NO: 108) PIK4CA2-5 sense 5' UGAUUGCAGUCGCGGACAAdTdT 3' (SEQ ID NO: 109) Antisense 5' UUGUCCGCGACUGCAAUCAdTdT 3' (SEQ ID NO: 110) PIK4CA2-6 sense 5' AAAGACUACUCCAACUUCAdTdT 3' (SEQ ID NO: 111) Antisense 5' UGAAGUUGGAGUAGUCUUUdTdT 3' (SEQ ID NO: 112) Result: All six siRNAs targeting PIK4CA inhibited HCV subgenomic replication, confirming that isoform 2 of PIK4CA is the relevant isoform for HCV replication. Example 10: siRNAs Targeting PIK4CA Knock Down PIK4CA mRNA Levels Prior to Disrupting HCV Replication If HCV replication is dependent upon PIK4CA expression or activity, the decrease in HCV replication occurring after transfection of PIK4CA-targeting siRNA should occur subsequent to loss of PIK4CA expression. To verify this, HuH-7 cells containing the HCV Con1-lb replicon were transfected with siRNA targeting PIK4CA. At 0, 12, 24, 36, 48, 60 and 72 h following transfection, total RNA was isolated from the cells and PIK4CA and HCV RNA levels were determined as described in Example 6. Results As shown in Figure 1, siRNAs targeting PIK4CA lead to maximal inhibition of PIK4CA mRNA levels at between 12 and 24 h post-transfection. In contrast, HCV RNA levels begin to decrease between 36 and 48 h post-transfection and continue to decrease through the 72 h time point. Example 11: Validation of knock down of PIK4CA Protein Levels Using a Polyclonal PIK4CA antibody Antibodies were raised against antigens IP1240 SEQ ID NO: 113 (aa 893-904) and IP1241 SEQ ID NO: 114 (aa 696-707). Antisera from two of the rabbits (D3792 and D3793) was sensitive enough to detect endogenous levels of PIK4CA when assayed by western blot. V5-tagged PIK4CA or empty pCDNA 3.1 vectors were over-expressed in HCV HIB 1 Conlb cells. The cell lysates were harvested in RIPA buffer and loaded on a 4% Tris-Glycine SDS-PAGE Gel. The custom antibodies (1mg/ml) were diluted 1:1000 for western blot analysis using the Licor Odyssey Imaging system. To determine the gel migration characteristics of PIK4CA, we performed a dual-probe western blot using the V5 and D3972 antibodies. The dual color western blot demonstrates that the less intense, lower band seen in the D3972 blot migrates at the same size as the V5-tagged protein (Figure 2A). To determine if the PIK4CA protein is reduced in the presence of PIK4CA siRNA, we transfected HCV HB1 Con1lb cells with control siRNAs as well as PIK4CA siRNAs targeting the ORF or the 3'UTR of the PIK4CA mRNA. The results demonstrate that HCV RNA levels are reduced by PIK4CA siRNAs as well as the positive control, HCV siRNA (Figure 2B). In addition, the PIK4CA siRNAs targeting both the ORF and 3'UTR of the PIK4CA mRNA reduce PIK4CA protein to - 25 - WO 2007/001928 PCT/US2006/023646 undetectable levels by western blot (as noted above, the lower, less intense band represents PIK4CA, Figure 2C). These data both validate the knockdown of PIK4CA protein levels by the siRNAs used and also confirm the identity of the PIK4CA band recognized by the D3972 antibody. Example 12: Additional Information on Some Targets Additional information on some of the targets is provided below: DUSP19 (Dual Specificity Phosphatase 19) DUSPl9 is a member of a family of dual specificity mitogen-activated protein kinase phosphatases. The protein sequence and encoding cDNA sequence are provided by SEQ ID NOs: 49 and 50. DUSP19 polymorphisms are shown in Table 5. TABLE 5 mRNA position NM 080876 seq Polymorphism NP 543152 seq Amino Acid change 830 T G Ser Arg DUT (dUTP Pyrophosphatase) DUT maintains dUTP at low levels to prevent misincorporation into DNA during replication, mediates resistance to 5-fluorouracil, and may regulate peroxisome proliferation. The protein sequence and encoding cDNA sequences are provided by SEQ ID NOs: 51 and 52. DUT polymorphisms are shown in Table 6. TABLE 6 mRNA position NM_001948 seq Polymorphism NP_001939 seq Amino Acid change 545 G T Gly Val 565 A C Thr Pro DYRK4 (Dual Specificity Tyrosine-Regulated Kinase 4) DYRK4 is a member of the DYRK family of protein tyrosine kinases. The protein sequence and encoding cDNA sequences are provided by SEQ ID NOs: 53 and 54. DYRK4 polymorphisms are shown in Table 7. TABLE 7 mRNA position NM_003845 seq Polymorphism NP_003836 seq Amino Acid change 284 C T Leu42 No Change 341 G A Ala61 Thr -26 - WO 2007/001928 PCT/US2006/023646 445 C T Val95 No change 726 A G Asnl89 Ser 1135 C T Ala325 No Change 1433 G C Glu425 Gin 1521 A T Asp454 Val GAK (Cyclin G Associated Kinase) GAK is a putative serine/threonine protein kinase that shares homology with tensin and auxilin, and may play a role in cell cycle regulation. The protein sequence and encoding cDNA sequence for GAK are provided by SEQ ID NOs: 55 and 56. GAK nucleotide polymorphisms are shown in Table 8 TABLE 8 mRNA position NM_005255 seq Polymorphism NP_005246 seq Amino Acid change 3891 C T Asp1297 No Change 3889 G A Asp1297 Asn 3819 T C Ala1273 No change 3794 A G Lys1265 Arg 3135 A G Ala1045 No change 3003 C T Serl001 No change 2618 A C Glu873 Ala 2330 A G Asp779 Gly 1457 A G Tyr486 Cys 1237 A G Ile413 Val 1197 C T Ser399 No change PARVB (Parvin beta) Isoform A: PARVB is a focal adhesion protein containing two calponin homology domains that binds integrin-linked kinase and is likely involved in integrin-ILK signaling to establish cell-substrate adhesion. The protein sequence and encoding cDNA sequence for PARVB are provided by SEQ ID NOs: 37 and 38. PARVB nucleotide polymorphisms are shown in Table 9. TABLE 9 mRNA position NM_013327 seq Polymorphism NP 037459 seq Amino Acid change 225 T C Val58 Ala - 27 - WO 2007/001928 PCT/US2006/023646 253 T C Leu67 No Change 790 C T Phe246 No change 1015 C T Phe321 No change PFKL (Phosphofructokinase, liver) Liver phosphofructokinase catalyses the phosphorylation of fructose-6-phosphate to fructose-1,6-bisphosphate in glycolysis. Deficiency is linked to glycogenosis type VII while overexpression may lead to the cognitive disabilities of Down's syndrome. The protein and encoding cDNA sequence for PFKL are provided by SEQ ID NOs: 63 and 64. PIK4CA PIK4CA is a type III phosphatidylinositol-4 kinase. It catalyzes the first step in the Formation of phosphatidylinositol 4,5-bisphosphate and its activity is inhibited by high concentrations of wortmannin. The protein and encoding cDNA sequence for PIK4CA are provided by SEQ ID NOs: 21 and 22. PIK4CA nucleotide polymorphisms are shown in Table 10. TABLE 10 mRNA position NM_058004 seq Polymorphism NP 477352 seq Amino Acid change 6119 A T Asn2040 Ile2040 5734 T C Glyl911 No change 5613 T C Thrl871 No change 5505 C T Cysl835 No change 5377 G C Va11793 Leu1793 5376 G A Lys1792 No change 5305 G T Asp1769 Tyr1769 4869 G A Gln1623 No change 3903 C T Leul301 No change 3854 C T His1284 No change 3826 G A Gly1276 Arg1276 3603 G A Thrl201 No change PSKH1 (Protein Serine Kinase H1) PSKH1 is a protein serine kinase that undergoes calcium-dependent autophosphorylation. Overexpression of PSKH1 leads to nuclear reorganization of splicing factors SFRS 1 and SFRS2 and stimulates RNA splicing. The protein and encoding cDNA sequence for PSKH1 are provided by SEQ ID NOs: 57 and 58. - 28 - WO 2007/001928 PCT/US2006/023646 SOCS5 (Suppressor of Cytokine Signaling 5) SOCS5 is a cytokine-inducible protein containing an SH2 domain and a SOCS box. It negatively regulates cytokine signaling via the JAK-STAT pathways. The protein and encoding cDNA sequence for SOCS5 are provided by SEQ ID NOs: 59 and 60. Nucleotide polymorphisms identified for SOCS5 are shown in Table 11. TABLE 11 mRNA position NM 014011 seq Polymorphism NP 054730 seq Amino Acid change 911 A G Thr249 No change 1296 G A Gly378 Arg 1634 G A Ala490 No change SYNPR (Synaptoporin) Synaptoporin is a protein with high homology to rat synaptophysin, an integral membrane synaptic vesicle protein involved in targeting of synaptic vesicles. It contains a membrane associating domain, often found in lipid-associating proteins. The protein and encoding cDNA sequence for SYNPR are provided by SEQ ID NOs: 45 and 46. TRPM5 (Transient Receptor Potential Cation Channel, Subfamily M, Member 5) TRPM5 is related to the transient receptor potential family of cation channels. It has six predicted transmembrane domains. The protein and encoding cDNA sequence for TRPM5 are provided by SEQ ID NOs: 47 and 48. Nucleotide polymorphisms identified for TRPM5 are presented in Table 12. TABLE 12 mRNA position NM_014555 seq Polymorphism NP 055370 seq Amino Acid change 3291 G T Gly1094 No change 2517 G A Thr836 No change 1752 T C Leu581 No change 1742 G A Arg578 Gln578 1270 C T Ser421 No change 770 T C Val254 Ala254 756 G A Pro249 No change 713 A G Asn235 Ser235 -29 - WO 2007/001928 PCT/US2006/023646 PAFAHIB] (Platelet-Activating Factor Acetylhydrolase (Isoform lb) Alpha Subunit (45kD) PAFAH1B 1 is the noncatalytic subunit of a heterotrimeric enzyme that inactivates platelet-activating factor. The protein and encoding cDNA sequence for PAFAH1B 1 are provided by SEQ ID NOs: 35 and 36. Nucleotide polymorphisms for PAFAH1B1 are shown in Table 13. TABLE 13 mRNA position NM_000430 seq Polymorphism NP_000421 seq Amino Acid change 1248 A T Thr 231 No change 1614 T C Ile 353 No change STKJ6 (Serine/Threonine Kinase 16) Serine/threonine kinase 16 is a myristoylated and palmitoylated protein kinase that may regulate transcription in response to signaling by transforming growth factor beta. The protein and encoding cDNA sequence for STK16 are provided by SEQ ID NOs: 7 and 8. TNKI (Tyrosine Kinase,Non-receptor 1) TNK1 is a kinase that interacts with phospholipase C gamma 1 (PLCG1). It may regulate phospholipid signaling pathways during fetal development and in adult cells of the lymphohematopoietic system. The protein and encoding cDNA sequence for TNK1 are provided by SEQ ID NOs: 61 and 62. Example 13: siRNA hits that also block HIV Infection High priority siRNA pools were tested for their ability to disrupt HIV infection in HeLa cells. The procedure was performed as follows: Day 1: Plate HeLa (P4/R5) cells at 2000 cells per well in 4x96-well plates. Day 2: Transfect HeLa (P4/R5) cells with siRNA pools as follows: 1. siRNAs were transfected at a final concentration of 100 nM using OligofectamineTM reagent (Invitrogen) at a final concentration of 0.5%. Positive and negative control siRNAs are included as follows: Cyclin T1 (positive control): purchased from Santa Cruz Biotechnology (Cat. No. sc-35144) Luciferase (negative control): CGUACGCGGAAUACUUCGAdTdT (SEQ ID NO: 115) siRNAs tested in duplicate included a pool of 3 siRNAs targeting: DUSP19, DUT, DYRK4 GAK, PARVB, PFKL, PIK4CA, PSKHI1, SOCS5, SYNPR and TRPM5 2. Dispensed 66 pL of OptiMEM/ well into a sterile 96-well plate, leaving the 12 t column empty. 3. Transferred 2 pL of each siRNA (resuspended at 10 pM) into the OptiMEM-containing plate. 4. Mixed by pipetting up and down. - 30 - WO 2007/001928 PCT/US2006/023646 5. In a tube, added 240 pL Oligofectamine, 1210 pL OptiMEM. Incubated 5 minutes at room temperature. 6. Dispensed 12 pL of the Oligofectamine to each well and mixed by pipetting up and down. Incubated the plate at room temperature for 15 minutes. 7. Added 20 pL of the siRNA-Oligofectamine complex to each well of the HeLa (P4/R5) cells. Day 3: Transfected HeLa (P4/R5) cells were infected with HXB2 HIV as follows: 1. Media was removed from the cells. 2. 80 pL fresh media was added to each well. 3. HXB2 HIV was diluted with media. 40 pL of diluted HXB2 was added to each well. 4. Viral infection was allowed to proceed for 96 hours. Day 5: Beta-galactosidase activity, an indication of viral infection, was measured as follows: 1. Media was removed from the cells. 2. Cells were washed with 200 pIL PBS per well. 3. 20 pL lysis buffer (Galacto-Light Plus, Tropix, Cat. No. BL100P) containing DTT was added to each well, and the plates were shaken for 10 minutes. 4. 80 pL of substrate was then added to each well and the plates were incubated at room temperature in the dark for 1 hour. 5. 100 pL of enhancing solution was added to each well and the plates were read using a Dynex luminometer. Data was analyzed in the following manner. Readings for each plate were normalized to the reading for the luciferase negative control and expressed as "percent of Luciferase Control". Preferred targets were considered to be those siRNA pools that suppressed beta-galactosidase activity by an average of 40% or more. Results: siRNAs targeting PIK4CA, SYNPR, DYRK4, and PFKL inhibited HIV replication by greater than 40% (see Figure 3). Thus, these genes are essential for the replication of both HIV and HCV in human cell lines. Between 30 and 40% inhibition of HIV replication was also observed with siRNAs targeting GAK, DUSP19, and DUT, indicating these genes may also be targets for HIV infection. As in Example 7, toxicity associated with SOCS5, PARVB, and TRPM5 siRNAs in HeLa cells precludes any understanding of the role these genes play in viral infection in these cells. No effect on HIV replication was observed with PSKH1 siRNAs. Other embodiments are within the following claims. While several embodiments have been shown and described, various modifications may be made without departing from the spirit and scope of the present invention. -31-

Claims (20)

1. A method of identifying a host cell factor involved in replication of a virus comprising the step of measuring the ability of a siRNA library targeting different cell factors to inhibit replication of said virus, wherein said siRNA library comprises at least 10 different siRNA's targeting a different host factor that was not previously associated with replication of said virus.
2. The method of claim 1, wherein said virus is a hepatitis C virus (HCV) and where said siRNA library comprises at least 100 different siRNA's targeting a different host factor that was not previously associated with HCV replication.
3. The method of claim 2, wherein each of said at least 100 different siRNA's is either a kinase or phosphatase.
4. A method of screening for a virus inhibitory compound comprising the steps of: (a) identifying a compound binding to, or inhibiting the activity or expression of, a target protein selected from the group consisting of: AKAP8 (SEQ ID NO: 11), ALK (SEQ ID NO: 67), ATM (SEQ ID NO: 68), C140RF24 (SEQ ID NO: 69), DGKD (SEQ ID NO: 15), DGKZ (SEQ ID NO: 70), DUSP19 (SEQ ID NO: 49), DUSP22 (SEQ ID NO: 71), DUSP6 (SEQ ID NO: 9), DUT (SEQ ID NO: 51), DYRK2 (SEQ ID NO: 72), DYRK4 (SEQ ID NO: 53), ENPP5 (SEQ ID NO: 73), EPHA2 (SEQ ID NO: 13), FGFR2 (SEQ ID NO: 74), FHIT (SEQ ID NO: 75), FRK (SEQ ID NO: 76), GAK (SEQ ID NO: 55), GCK (SEQ ID NO: 19), MAP2K3 (SEQ ID NO: 77), NME4 (SEQ ID NO: 1), PANK1 (SEQ ID NO: 78), PCK1 (SEQ ID NO: 3), PFKL (SEQ ID NO: 63), PIK4CA (SEQ ID NO: 21), PRKWNK3 (SEQ ID NO: 5), PRPS 1L1 (SEQ ID NO: 79), PSKH1 (SEQ ID NO: 57), PTK9L (SEQ ID NO: 80), SOCS5 (SEQ ID NO: 59), SRPK1 (SEQ ID NO: 17), STK16 (SEQ ID NO: 7), STK35 (SEQ ID NO: 81), TAF1 (SEQ ID NO: 82), TBK1 (SEQ ID NO: 83), TJP2 (SEQ ID NO: 84), TNK1 (SEQ ID NO: 61), TPK1 (SEQ ID NO: 85), TRIB3 (SEQ ID NO: 86), TRPM7 (SEQ ID NO: 87), VRK (SEQ ID NO: 88), ALPPL2 (SEQ ID NO: 89), AP4M1 (SEQ ID NO: 23), CAPZA1 (SEQ ID NO: 25), DNAH5 (SEQ ID NO: 27), DOM3Z (SEQ ID NO: 90), FTCD (SEQ ID NO: 29), PDIA3 (SEQ ID NO: 31), MDM4 (SEQ ID NO: 91), WDR66 (SEQ ID NO: 92), NOP5/NOP58 (SEQ ID NO: 33), NSUN6 (SEQ ID NO: 93), PAFAHIB 1 (SEQ ID NO: 35), PARVB (SEQ ID NO: 37), PHEX (SEQ ID NO: 39), PKN1 (SEQ ID NO: 44), POLR2J2 (SEQ ID NOs: 41 or 65), RAB20 (SEQ ID NO 43), SYNPR (SEQ ID NO: 45), and TRPM5 (SEQ ID NO: 47); or a protein substantially similar to said target protein, wherein said substantially similar protein has a sequence identity of at least 95% to said target protein; and (b) determining the ability of said compound identified in said step (a) to inhibit replication of said virus. - 32 - WO 2007/001928 PCT/US2006/023646
5. The method of claim 4, wherein said target protein is either SEQ ID NO: 21, 45, 47, 49, 51, 53, 55, or 63, or a substantially similar protein having a sequence identity of at least 95% to said target protein.
6. The method of claim 5, wherein said target protein is either SEQ ID NO: 21, 45, 47, 53, or 63.
7. The method of claim 4, wherein said virus is either hepatitis C virus (HCV) or human immunodeficiency virus (HIV).
8. The method of claim 5, wherein said compound identified in said step (a) inhibits the activity of said target protein.
9. The method of claim 8, wherein said virus is HCV and said target protein is either SEQ ID NO: 7, 21, 35, 37, 45, 47, 49, 51, 53, 55, 57, 59, 61, or 63, or a substantially similar protein having a sequence identity of at least 95% to said target protein.
10. The method of claim 9, wherein said target protein is either SEQ ID NO: 7, 21, 35, 37, 45, 47, 49, 51, 53, 55, 57, 59, 61, or 63.
11. The method of claim 10, wherein said step (b) is performed using a cultured cell containing an HCV replicon.
12. The method of claim 8, wherein said virus is HIV and said target protein is either SEQ ID NO: 21, 45, 47, 49, 51, 53, 55, or 63, or a substantially similar protein having a sequence identity of at least 95% to said target protein.
13. The method of claim 12, wherein said target protein is either SEQ ID NO: 21, 45, 47, 53, or 63.
14. A method of inhibiting hepatitis C virus (HCV) replication in a cell containing an HCV replicon or infected with HCV comprising the step of providing to said cell an effective amount of a compound able to inhibit the activity or expression of a target protein selected from the group consisting of: AKAP8 (SEQ ID NO: 11), ALK (SEQ ID NO: 67), ATM (SEQ ID NO: 68), C140RF24 (SEQ ID NO: 69), DGKD (SEQ ID NO: 15), DGKZ (SEQ ID NO: 70), DUSP19 (SEQ ID NO: 49), DUSP22 (SEQ ID NO: 71), DUSP6 (SEQ ID NO: 9), DUT (SEQ ID NO: 51), DYRK2 (SEQ ID NO: 72), DYRK4 (SEQ ID NO: 53), ENPP5 (SEQ ID NO: 73), EPHA2 (SEQ ID NO: 13), FGFR2 (SEQ ID NO: 74), FHIT (SEQ ID NO: 75), FRK (SEQ ID NO: 76), GAK (SEQ ID NO: 55), GCK (SEQ ID NO: -33- WO 2007/001928 PCT/US2006/023646 19), MAP2K3 (SEQ ID NO: 77), NME4 (SEQ ID NO: 1), PANK1 (SEQ ID NO: 78), PCK1 (SEQ ID NO: 3), PFKL (SEQ ID NO: 63), PIK4CA (SEQ ID NO: 21), PRKWNK3 (SEQ ID NO: 5), PRPS1L1 (SEQ ID NO: 79), PSKH1 (SEQ ID NO: 57), PTK9L (SEQ ID NO: 80), SOCS5 (SEQ ID NO: 59), SRPK1 (SEQ ID NO: 17), STK16 (SEQ ID NO: 7), STK35 (SEQ ID NO: 81), TAF1 (SEQ ID NO: 82), TBK1 (SEQ ID NO: 83), TJP2, TNK1 (SEQ ID NO: 61), TPK1 (SEQ ID NO: 85), TRIB3 (SEQ ID NO: 86), TRPM7 (SEQ ID NO: 87), VRK (SEQ ID NO: 88), ALPPL2 (SEQ ID NO: 89), AP4M1 (SEQ ID NO: 23), CAPZA1 (SEQ ID NO: 25), DNAH5 (SEQ ID NO: 27), DOM3Z (SEQ ID NO: 90), FTCD (SEQ ID NO: 29), PDIA3 (SEQ ID NO: 31), MDM4 (SEQ ID NO: 91), WDR66 (SEQ ID NO: 92), NOP5/NOP58 (SEQ ID NO: 33), NSUN6 (SEQ ID NO: 93), PAFAH1B 1 (SEQ ID NO: 35), PARVB (SEQ ID NO: 37), PHEX (SEQ ID NO: 39), PKN1 (SEQ ID NO: 44), POLR2J2 (SEQ ID NOs: 41 or 65), RAB20 (SEQ ID NO 43), SYNPR (SEQ ID NO: 45), and TRPM5 (SEQ ID NO: 47); or a protein substantially similar to said target protein, wherein said substantially similar protein has a sequence identity of at least 95% to said target protein.
15. The method of claim 14, wherein said target protein is either SEQ ID NO: 7, 21, 35, 37, 45, 47, 49, 51, 53, 55, 57, 59, 61, or 63, or a substantially similar protein having a sequence identity of at least 95% to said target protein.
16. The method of claim 15, wherein said method is used to inhibit HCV replication in a cultured cell infected with an HCV replicon.
17. A method of inhibiting replication of a virus in a host comprising the step of providing to said host cell an effective amount of a compound able to inhibit the activity or expression of a target protein selected from the group consisting of: AKAP8 (SEQ ID NO: 11), ALK (SEQ ID NO: 67), ATM (SEQ ID NO: 68), C140RF24 (SEQ ID NO: 69), DGKD (SEQ ID NO: 15), DGKZ (SEQ ID NO: 70), DUSP19 (SEQ ID NO: 49), DUSP22 (SEQ ID NO: 71), DUSP6 (SEQ ID NO: 9), DUT (SEQ ID NO: 51), DYRK2 (SEQ ID NO: 72), DYRK4 (SEQ ID NO: 53), ENPP5 (SEQ ID NO: 73), EPHA2 (SEQ ID NO: 13), FGFR2 (SEQ ID NO: 74), FHIT (SEQ ID NO: 75), FRK (SEQ ID NO: 76), GAK (SEQ ID NO: 55), GCK (SEQ ID NO: 19), MAP2K3 (SEQ ID NO: 77), NME4 (SEQ ID NO: 1), PANK1 (SEQ ID NO: 78), PCK1 (SEQ ID NO: 3), PFKL (SEQ ID NO: 63), PIK4CA (SEQ ID NO: 21), PRKWNK3 (SEQ ID NO: 5), PRPS1L1 (SEQ ID NO: 79), PSKH1 (SEQ ID NO: 57), PTK9L (SEQ ID NO: 80), SOCS5 (SEQ ID NO: 59), SRPK1 (SEQ ID NO: 17), STK16 (SEQ ID NO: 7), STK35 (SEQ ID NO: 81), TAF1 (SEQ ID NO: 82), TBK1 (SEQ ID NO: 83), TJP2 (SEQ ID NO: 84), TNK1 (SEQ ID NO: 61), TPK1 (SEQ ID NO: 85), TRIB3 (SEQ ID NO: 86), TRPM7 (SEQ ID NO: 87), VRK (SEQ ID NO: 88), ALPPL2 (SEQ ID NO: 89), AP4M1 (SEQ ID NO: 23), CAPZA1 (SEQ ID NO: 25), DNAH5 (SEQ ID NO: 27), DOM3Z (SEQ ID NO: 90), FTCD (SEQ ID NO: 29), PDIA3 (SEQ ID NO: 31), MDM4 (SEQ ID NO: 91), WDR66 (SEQ ID NO: 92), NOP5/NOP58 (SEQ ID NO: 33), NSUN6 (SEQ ID NO: 93), PAFAH1B 1 (SEQ ID NO: 35), PARVB (SEQ ID NO: 37), PHEX (SEQ ID NO: 39), PKN1 -34 - WO 2007/001928 PCT/US2006/023646 (SEQ ID NO: 44), POLR2J2 (SEQ ID NOs: 41 or 65), RAB20 (SEQ ID NO 43), SYNPR (SEQ ID NO: 45), and TRPM5 (SEQ ID NO: 47); or a protein substantially similar to said target protein, wherein said substantially similar protein has a sequence identity of at least 95% to said target protein.
18. The method of claim 17, wherein said target protein is either SEQ ID NO: 7, 21, 35, 37, 45, 47, 49, 51, 53, 55, 57, 59, 61, or 63.
19. The method of claim 17, wherein said virus is hepatitis C virus (HCV) or human immunodeficiency virus (HIV).
20. The method of claim 19, wherein said target protein is either SEQ ID NO: 21, 45, 47, 53, or 63. -35-
AU2006262490A 2005-06-22 2006-06-16 Targets for inhibiting HCV replication Abandoned AU2006262490A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US69282105P 2005-06-22 2005-06-22
US60/692,821 2005-06-22
US71000605P 2005-08-19 2005-08-19
US60/710,006 2005-08-19
PCT/US2006/023646 WO2007001928A2 (en) 2005-06-22 2006-06-16 Targets for inhibiting hcv replication

Publications (1)

Publication Number Publication Date
AU2006262490A1 true AU2006262490A1 (en) 2007-01-04

Family

ID=37595694

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006262490A Abandoned AU2006262490A1 (en) 2005-06-22 2006-06-16 Targets for inhibiting HCV replication

Country Status (5)

Country Link
EP (1) EP1896619A2 (en)
JP (1) JP2009501513A (en)
AU (1) AU2006262490A1 (en)
CA (1) CA2611528A1 (en)
WO (1) WO2007001928A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2316943B1 (en) 2007-07-05 2013-06-19 Novartis AG DSRNA for treating viral infection
WO2009140624A2 (en) 2008-05-16 2009-11-19 Takeda San Diego, Inc. Glucokinase activators
US20100183704A1 (en) * 2008-09-25 2010-07-22 Novartis Ag dsRNA FOR TREATING VIRAL INFECTION
WO2010137570A1 (en) * 2009-05-29 2010-12-02 学校法人慶應義塾 Anti-viral agent or an anti-cancer agent
CN115003692A (en) * 2020-01-19 2022-09-02 北京生命科学研究所 Specific host factor for hepatitis B virus infection and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003223520A1 (en) * 2002-04-12 2003-10-27 Mitokor Targets for therapeutic intervention identified in the mitochondrial proteome
US20050101581A1 (en) * 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2

Also Published As

Publication number Publication date
EP1896619A2 (en) 2008-03-12
CA2611528A1 (en) 2007-01-04
JP2009501513A (en) 2009-01-22
WO2007001928A3 (en) 2011-05-26
WO2007001928A2 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
Ng et al. Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology
Yang et al. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro
Lam et al. PSI-7851, a pronucleotide of β-D-2′-deoxy-2′-fluoro-2′-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication
Francois et al. Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis
Robida et al. Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro
Howe et al. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796
US7148006B2 (en) Screening methods to identify agents that selectively inhibit hepatitis C virus replication
Lee et al. cis-acting RNA signals in the NS5B C-terminal coding sequence of the hepatitis C virus genome
Rumlová et al. In vitro methods for testing antiviral drugs
Kwon et al. The ribonuclease L-dependent antiviral roles of human 2′, 5′-oligoadenylate synthetase family members against hepatitis C virus
Vyas et al. Inhibition of the protein kinase PKR by the internal ribosome entry site of hepatitis C virus genomic RNA
AU2006262490A1 (en) Targets for inhibiting HCV replication
CN101854938A (en) Compositions and methods for the identification of inhibitors of retroviral infection
Kitano et al. Selection and characterization of rupintrivir-resistant Norwalk virus replicon cells in vitro
Wang et al. p53 promotes ZDHHC1-mediated IFITM3 palmitoylation to inhibit Japanese encephalitis virus replication
Schöbel et al. Hepatitis C virus infection restricts human LINE-1 retrotransposition in hepatoma cells
Kang et al. c-Fos regulates hepatitis C virus propagation
Choi et al. Nonstructural NS5A protein regulates LIM and SH3 domain protein 1 to promote hepatitis C virus propagation
Tripathi et al. Replication efficiency of chimeric replicon containing NS5A–5B genes derived from HCV-infected patient sera
Tanaka et al. Cellular peptidyl-prolyl cis/trans isomerase Pin1 facilitates replication of feline coronavirus
Heintges et al. Inhibition of hepatitis C virus NS3 function by antisense oligodeoxynucleotides and protease inhibitor
US9284555B2 (en) Aptazyme capable of selective silencing of target miRNA by releasing an antisense sequence in hepatitis C virus-infected cells and use thereof
Silberstein et al. Persistent growth of a human plasma-derived hepatitis C virus genotype 1b isolate in cell culture
US20140274935A1 (en) Methods for determining viral sensitivity to viral inhibitors
El Awady et al. Antisense oligonucleotide inhibition of hepatitis C virus genotype 4 replication in HepG2 cells

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application